MEDIPOST has conducted the first surgery in Hong Kong using knee cartilage stem cell treatment agent, CARTISTEM^®.

This is the first case where a stem cell agent developed and manufactured in Korea was used overseas.

Those working in the field are hoping that this will become the foundation for overseas export of stem cell research of Korea.

This surgery was conducted in an orthopedic hospital in Central Queens Road, at the center of Hong Kong on June 14th.

The patient was a man in his 50’s suffering from severe degenerative arthritis.

MEDIPOST signed a contract for sales of CARTISTEM^® with Hong Kong Life Science Co., Ltd last November, to work towards moving in to the Hong Kong market.

Regarding this, the project development manager of MEDIPOST, Jay Lee, commented that “At the moment, CARTISTEM^® is being supplied to limited patients through the authorized prescription system. However, we are aiming for starting mainstream sales through official sales permit during the year”.

He also added that “through this surgery, we hope to strengthen the marketing of the product for orthopedic doctors and arthritis patients in Hong Kong, Macau, China and Taiwan”